{'52WeekChange': 0.33108103,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Technologiepark',
 'address2': 'Im Neuenheimer Feld 582',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.94,
 'askSize': 4000,
 'averageDailyVolume10Day': 1284200,
 'averageVolume': 1584604,
 'averageVolume10days': 1284200,
 'beta': 2.881792,
 'beta3Year': None,
 'bid': 3.94,
 'bidSize': 4000,
 'bookValue': 0.669,
 'category': None,
 'circulatingSupply': None,
 'city': 'Heidelberg',
 'companyOfficers': [],
 'country': 'Germany',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.18,
 'dayLow': 3.925,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 300424608,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '49 6221 6743 649',
 'fiftyDayAverage': 4.084429,
 'fiftyTwoWeekHigh': 4.91,
 'fiftyTwoWeekLow': 1.42,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 60769646,
 'forwardEps': -0.4,
 'forwardPE': -9.85,
 'fromCurrency': None,
 'fullTimeEmployees': 137,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.07497,
 'heldPercentInstitutions': 0.59174,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/affimed.com',
 'longBusinessSummary': 'Affimed N.V., a clinical-stage biopharmaceutical '
                        'company, focuses on discovering and developing cancer '
                        'immunotherapies in the United States, Europe, and '
                        'Germany. Its lead product candidate is AFM13, a '
                        'natural killer cell (NK-cell) TandAb, which has '
                        'completed Phase 2a clinical study of relapsed '
                        'CD30-positive lymphoma and Phase 1b clinical study of '
                        'anti-PD-1 antibody Keytruda (pembrolizumab) in '
                        'patients with relapsed Hodgkin lymphoma. The company '
                        'is also developing AFM24, a tetravalent, bispecific '
                        'epidermal growth factor receptor, and CD16A-binding '
                        'innate cell engager for the treatment of advanced '
                        'cancer patients; AFM26, an innate cell-engaging '
                        'bispecific antibody targeting B cell maturation '
                        'antigen (BCMA) for the treatment of multiple myeloma; '
                        'and Trispecific antibodies for the treatment of '
                        'multiple myeloma. In addition, it is developing '
                        'AFM11, a T cell engager for the treatment of CD19+ B '
                        'cell malignancies, including non-Hodgkin Lymphoma and '
                        'acute lymphocytic leukemia (AML); and AMV564, a '
                        'CD33/CD3-specific T-cell TandAb that is in Phase 1 '
                        'clinical study of refractory AML. The company has '
                        'license agreements with Amphivena Therapeutics, Inc., '
                        'Deutsches Krebsforschungszentrum, and Xoma '
                        'Corporation; research funding agreement with The '
                        'Leukemia & Lymphoma Society; and collaboration with '
                        'Merck Sharp & Dohme B.V. It also has a clinical '
                        'development and commercialization collaboration with '
                        'The University of Texas MD Anderson Cancer Center to '
                        "evaluate AFM13 in combination with MD Anderson's "
                        'NK-cell product; and Genentech. The company was '
                        'formerly known as Affimed Therapeutics B.V. and '
                        'changed its name to Affimed N.V. in October 2014. '
                        'Affimed N.V. was founded in 2000 and is headquartered '
                        'in Heidelberg, Germany.',
 'longName': 'Affimed N.V.',
 'market': 'us_market',
 'marketCap': 300424640,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_849883',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.07,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '49 6221 6743 60',
 'previousClose': 4.11,
 'priceHint': 4,
 'priceToBook': 5.889387,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -2.79792,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.18,
 'regularMarketDayLow': 3.925,
 'regularMarketOpen': 4.07,
 'regularMarketPreviousClose': 4.11,
 'regularMarketPrice': 4.07,
 'regularMarketVolume': 1307734,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 76249904,
 'sharesPercentSharesOut': 0.0641,
 'sharesShort': 4887185,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2141503,
 'shortName': 'Affimed N.V.',
 'shortPercentOfFloat': 0.0672,
 'shortRatio': 2.43,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'AFMD',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.717,
 'twoHundredDayAverage': 2.8042445,
 'volume': 1307734,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.affimed.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '69120'}